Although (ART), when used concurrently with certain medications, has an increased risk of potential drug to drug interactions (PDDI), studies have suggested a low DDI profile of Biktarvy. Our objective of the study: is to evaluate such benefits of Biktarvy by assessing the evaluation of polypharmacy, PDDI, its effect on health-related quality of life, and adherence of HIV-infected subjects. Our Hypotheses: Is that by switching from Genvoya or Stibilid to Biktarvy we will decrease the number of PDDI, and improve patients health-related quality of life in older adults on polypharmacy.
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email firstname.lastname@example.org and someone will assist you.
Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact email@example.com.